Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial-Reference-Cited by-同舟云学术

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Published:2017-12 Issue:12 Volume:18 Page:1590-1599
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Shaw Alice T,Felip Enriqueta,Bauer Todd M,Besse Benjamin,Navarro Alejandro,Postel-Vinay Sophie,Gainor Justin F,Johnson Melissa,Dietrich Jorg,James Leonard P,Clancy Jill S,Chen Joseph,Martini Jean-François,Abbattista Antonello,Solomon Benjamin J

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J Clin Oncol,2012

2. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007

3. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

4. Crizotinib in ROS1-rearranged non-small-cell lung cancer;Shaw;N Engl J Med,2014

5. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

Cited by 545 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12

2. Clinical manifestation and outcome of lung cancer patients with ocular metastasis: 16 case reports and systematic review;Thoracic Cancer;2024-09-09

3. New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years;Journal of Clinical Oncology;2024-09-04

4. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

5. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification;Lung Cancer;2024-09